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No Shortcuts to Safer Opioid Prescribing
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Since the Centers for Disease Control and Prevention (CDC) released its Guideline for 
Prescribing Opioids for Chronic Pain in 2016,1 the medical and health policy communities 
have largely embraced its recommendations. A majority of state Medicaid agencies reported 
having implemented the guideline in fee-for-service programs by 2018, and several states 
passed legislation to increase access to nonopioid pain treatments.2 Although outpatient 
opioid prescribing had been declining since 2012, accelerated decreases — including in high 
risk prescribing — followed the guideline’s release.2,3 Indeed, guideline uptake has been 
rapid. Difficulties faced by clinicians in prescribing opioids safely and effectively, growing 
awareness of opioid-associated risks, and a public health imperative to address opioid 
overdose underscored the need for guidance and probably facilitated uptake. Furthermore, 
the guideline was rated as high quality by the ECRI Guidelines Trust Scorecard. In addition, 
the CDC (including the authors of this Perspective, who were also authors of the Guideline) 
engaged clinicians, health systems leaders, payers, and other decision makers in discussions 
of the Guideline’s intent and provided clinical tools, including a mobile application and 
training, to facilitate appropriate implementation.4
Efforts to implement prescribing recommendations to reduce opioid-related harms are 
laudable. Unfortunately, some policies and practices purportedly derived from the guideline 
have in fact been inconsistent with, and often go beyond, its recommendations. A consensus 
panel has highlighted these inconsistencies,5 which include inflexible application of 
recommended dosage and duration thresholds and policies that encourage hard limits and 
abrupt tapering of drug dosages, resulting in sudden opioid discontinuation or dismissal of 
patients from a physician’s practice. The panel also noted the potential for misapplication of 
the recommendations to populations outside the scope of the guideline. Such misapplication 
has been reported for patients with pain associated with cancer,5 surgical procedures,5 or 
acute sickle cell crises. There have also been reports of misapplication of the guideline’s 
dosage thresholds to opioid agonists for treatment of opioid use disorder. Such actions are 
likely to result in harm to patients.
We need better evidence in order to evaluate the benefits and harms of clinical decisions 
regarding opioid prescribing, including when and how to reduce high dose opioids in 
patients receiving them long term. The CDC developed the guideline on the basis of the best 
available evidence, with input from a multidisciplinary group that included experts in pain 
management as well as representatives of patients and the public. In situations for which the 
evidence is limited, it is particularly important not to extend implementation beyond the 
guideline’s statements and intent. And yet in some cases, the guideline has been 
misimplemented in this way.
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For example, the guideline states that “Clinicians should … avoid increasing dosage to ≥90 
MME [morphine milligram equivalents]/day or carefully justify a decision to titrate dosage 
to ≥90 MME/day.”1 This statement does not address or suggest discontinuation of opioids 
already prescribed at higher dosages, yet it has been used to justify abruptly stopping opioid 
prescriptions or coverage.5 This recommendation also does not apply to dosing for 
medication-assisted treatment for opioid use disorder. The CDC based the recommendation 
on evidence of dose-dependent harms of opioids and the lack of evidence that higher 
dosages confer long-term benefits for pain relief. However, we know little about the benefits 
and harms of reducing high dosages of opioids in patients who are physically dependent on 
them.
Patients who are able to successfully taper their opioid use are likely to have a lower risk of 
overdose, and evidence is accumulating that they might experience reduced pain.4 Other 
patients may find tapering challenging; could face risks related to withdrawal symptoms, 
increased pain, or unrecognized opioid use disorder; and if their dosages are abruptly 
tapered may seek other sources of opioids or have adverse psychological and physical 
outcomes. Policies should allow clinicians to account for each patient’s unique 
circumstances in making clinical decisions.
The guideline offers guidance for caring for patients who are already taking opioid dosages 
of 90 MME or more per day long term, including guidance on when tapering the dose might 
be appropriate, the importance of empathetically reviewing risks associated with continuing 
high-dose opioids, collaborating with patients who agree to taper their dose, maximizing 
nonopioid treatment, and tapering slowly enough to minimize withdrawal symptoms. 
Patients exposed to high dosages for years may need slower tapers (e.g., 10% per month, 
though the pace of tapering may be individualized).1 Success might require months to years. 
Though some situations, such as the aftermath of an overdose, may necessitate rapid tapers, 
the guideline does not support stopping opioid use abruptly.1
Guidelines can improve patient outcomes when they lead to policies that reduce harm, while 
offering support and coverage for underused services (e.g., nonpharmacologic strategies, 
naloxone coprescribing,and treatment for opioid use disorder). However, policies invoking 
the opioid-prescribing guideline that do not actually reflect its content and nuances can be 
used to justify actions contrary to the guideline’s intent. The CDC has engaged quality-
improvement organizations, payers, federal partners, state health departments, and others in 
discussions to encourage adherence to recommendations while avoiding actions that might 
cause harm. For example, the CDC worked with the American Society of Addiction 
Medicine to clarify that dosage thresholds in the guideline should not direct dosing of 
medication-assisted treatment for opioid use disorder.
Even guideline-concordant care can be challenging. Implementing recommendations with 
individual patients takes time and effort. An unintended consequence of expecting clinicians 
to mitigate risks of high-dose opioids is that rather than caring for patients receiving high 
dosages or engaging and supporting patients in efforts to taper their dosage, some clinicians 
may find it easier to refer or dismiss patients from care. Clinicians might universally stop 
prescribing opioids, even in situations in which the benefits might outweigh their risks. Such 
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actions disregard messages emphasized in the guideline that clinicians should not dismiss 
patients from care, which can adversely affect patient safety, could represent patient 
abandonment, and can result in missed opportunities to provide potentially lifesaving 
information and treatment.1
Effective implementation of the guideline requires recognition that there are no shortcuts to 
safer opioid prescribing (which includes assessment of benefits and risks, patient education, 
and risk mitigation) or to appropriate and safe reduction or discontinuation of opioid use. 
Starting fewer patients on opioid treatment and not escalating to high dosages in the first 
place will reduce the numbers of patients prescribed high dosages in the long term. In the 
meantime, clinicians can maximize use of nonopioid treatments, review with patients the 
benefits and risks of continuing opioid treatment, provide interested and motivated patients 
with support to slowly taper opioid dosages, closely monitor and mitigate overdose risk for 
patients who continue to take high-dose opioids, and offer or arrange medication-assisted 
treatment when opioid use disorder is identified. The CDC offers several tools to assist, 
including a pocket guide on tapering, a mobile app and online training with motivational 
interviewing components, and information about nonopioid treatments for pain.4 We are 
also working to identify ways to integrate recommendations into medical education and to 
support best practices among the next generation of medical professionals.
Appropriate implementation of the guideline includes maximizing use of physical, 
psychological, and multimodal pain treatments. However, these therapies have not been 
used, available, or reimbursed sufficiently. The CDC has supported research to better define 
the evidence and coverage gaps for nonopioid pain treatments and has articulated the need to 
improve insurance coverage. 2,4 Efforts to support more judicious opioid use will become 
more successful as effective nonopioid treatments are increasingly available and used.
The CDC is evaluating the (intended and unintended) impact of the guideline and other 
health system strategies on clinician and patient outcomes and is committed to updating 
recommendations when new evidence is available. The CDC is funding the Agency for 
Healthcare Research and Quality to conduct systematic reviews on the effectiveness of 
opioid, nonopioid pharmacologic, and nonpharmacologic treatments for acute and chronic 
pain. Results of these reviews will assist in identifying research priorities and determining 
when evidence gaps are sufficiently addressed to warrant a guideline update or expansion. 
Until then, we encourage implementation of recommendations consistent with the 
guideline’s intent.
The views expressed in this article are those of the authors and do not necessarily represent 
the official position of the Centers for Disease Control and Prevention. Disclosure forms 
provided by the authors are available at NEJM.org.
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